TriRx Completes Acquisition of Elanco Manufacturing Facility

TriRx Pharmaceutical Services, an international contract development and manufacturing organization ( CDMO ), has finalized and closed on its agreement with Elanco Animal Health to acquire the ownership and operations of its manufacturing site in Speke, UK. Elanco is one of the world's leading animal health companies, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The two companies agreed a two-facility sale and long-term supply agreement in 2021, covering a facility in Shawnee, KS, and the Speke, UK site.
"The Speke facility deal constitutes the second part of our acquisition and supply agreement with Elanco, following our closing on the Shawnee, Kansas facility in August 2021,” said Timothy C. Tyson, chairman CEO, TriRx. “We look forward to continuing our successful strategic partnership with this global leader. This important two-facility acquisition represents a significant step in our strategy to be a leading global CDMO in both animal health and human health. We welcome the skilled workforce at Speke to TriRx, and look forward to growing this team as we invest in the site, fulfilling the long-term supply agreement with Elanco Animal Health and bringing in new business as part of our strategic plan."
The Speke facility, initially built by Eli Lilly, offers capabilities to manufacture human health and animal health products. The sale includes the physical assets of the site and transfer of approximately 350 employees. Under the long-term supply agreement, TriRx will continue to provide Elanco with reliable delivery of its products.
James Scandura, COO, TriRx, said, "The Speke facility is located close to Liverpool, UK, which is strategically important for TriRx. It is the fifth location for us and takes us to two manufacturing facilities in North America and two in Europe. It also adds API and biological capabilities to our portfolio, and further capacity capable of manufacturing both animal health and human health products."